On Friday, a federal judge issued a decision in Texas v. United States, finding the Affordable Care Act to be unconstitutional. This decision could ultimately leave people with pre-existing conditions, like cystic fibrosis, without patient protections while also jeopardizing access to adequate, affordable health care coverage.
The 24th annual Ultimate Golf Experience brought together a standout array of entertainers, guests, and friends of the Cystic Fibrosis Foundation for a premier golfing event to raise funds in the fight against cystic fibrosis.
Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
President Donald Trump signed an executive order on health care that could weaken patient protections. He also announced a plan to stop paying cost-sharing reduction (CSR) subsidies to health insurance companies. Both decisions could negatively affect people with cystic fibrosis.
Recipients include eight innovative programs from around the country that serve the CF community.
On Oct. 4, the Warren Alpert Foundation honored five CF scientists, including Dr. Francis Collins, for their trailblazing work in CF research. The Foundation received special acknowledgement for our role in driving this progress, marking the first time that an organization has been recognized by the Alpert Foundation.
In the wake of Hurricane Florence, the Cystic Fibrosis Foundation is offering two vital resources to support CF families affected by this hurricane and its surge.
Today, the U.S. Food and Drug Administration approved the use of ivacaftor (Kalydeco®) for children with cystic fibrosis ages 1 to 2 who have at least one mutation that is responsive to ivacaftor.
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.